Vir Biotechnology doses first patient in Phase 1 part 3 trial of VIR-5500

Vir Biotechnology (VIR) “announced that the first patient has been dosed in Part 3 of the Company’s Phase 1 clinical trial evaluating VIR-5500 in combination with androgen receptor pathway inhibitors. VIR-5500 is an investigational PRO-XTEN(R) dual-masked T-cell engager targeting prostate-specific membrane antigen and will be evaluated in participants in first-line pre-taxane metastatic castration-resistant prostate cancer. VIR-5500 is the only dual-masked PSMA-targeting TCE currently in clinical trials. The Phase 1 clinical trial is an open-label, non-randomized study designed to assess the safety, pharmacokinetics and preliminary anti-tumor activity of VIR-5500 in combination with ARPIs in participants with metastatic prostate cancer. VIR-5500 is currently being evaluated in the same Phase 1 clinical trial as a monotherapy and has demonstrated promising early anti-tumor activity and a favorable safety profile in heavily pre-treated patients with mCRPC. VIR-5500 incorporates the universal PRO-XTEN(R) masking technology, which is designed to enable the selective activation of the TCEs in the tumor microenvironment, mitigating damage to healthy cells and reducing toxicity.”